← Back
NeuroTrials.ai
Neurology Clinical Trial Database

ASTER

Contact Aspiration vs Stent Retriever for Successful Revascularization

Year of Publication: 2017

Authors: Bertrand Lapergue, Raphael Blanc, Benjamin Gory, ..., for the ASTER Trial Investigators

Journal: JAMA

Link: https://doi.org/10.1001/jama.2017.9644


Clinical Question

Does first-line contact aspiration result in an increased successful revascularization rate compared with first-line use of a stent retriever in patients with acute ischemic stroke undergoing thrombectomy?

Bottom Line

First-line contact aspiration did not result in increased successful revascularization compared with first-line use of a stent retriever. No significant differences were found in clinical outcomes or adverse events.

Major Points

  • First multicenter RCT comparing contact aspiration (ADAPT technique) vs stent retriever as first-line thrombectomy technique — 381 patients at 8 French neurointerventional centers.
  • Primary endpoint (successful revascularization, mTICI 2b/3) was similar: 85.4% aspiration vs 83.1% stent retriever (OR 1.20, 95% CI 0.68–2.10, P=0.53) — no superiority of aspiration.
  • No significant difference in functional independence at 90 days (45.3% aspiration vs 50.0% stent retriever) — clinical outcomes were equivalent between techniques.
  • Aspiration showed a trend toward faster procedure time (38 vs 45 min puncture-to-revascularization, P=0.10) but required more rescue therapy (32.8% vs 23.8%, P=0.05).
  • Similar safety profiles: sICH 5.3% vs 6.5%, mortality 15.4% vs 11.5% — no significant differences in any adverse event category.
  • Established clinical equipoise between the two main thrombectomy approaches — operators can choose based on anatomy, clot characteristics, and personal expertise.
  • Higher rescue therapy rate in aspiration group suggests first-pass aspiration alone is less reliable, but allowing rescue makes the overall approach equivalent.
  • Confirmed by subsequent ASTER-2 (2021, aspiration vs combined approach) and COMPASS (2019, aspiration vs stent retriever) — consistent finding of technique equivalence.
  • All centers had high expertise in both techniques — results may not apply to centers where operators are more experienced with one approach over the other.
  • Powered for superiority (15% absolute difference) — the trial cannot exclude smaller but clinically meaningful differences between techniques, nor prove noninferiority.

Design

Study Type: Randomized, multicenter, open-label, blinded end-point clinical trial

Randomization: 1

Blinding: Open-label, blinded endpoint assessment (PROBE)

Enrollment Period: 2015–2017

Follow-up Duration: 90 days

Centers: 8

Countries: France

Sample Size: 381

Analysis: Intention-to-treat; chi-squared test for primary endpoint; logistic regression for adjusted analyses


Inclusion Criteria

  • Age ≥18 years with acute ischemic stroke due to anterior circulation large vessel occlusion (ICA or M1)
  • Within 6 hours of symptom onset (or within extended window if perfusion imaging criteria met)
  • NIHSS ≥2 at randomization
  • Pre-stroke mRS 0–1
  • Eligible for endovascular thrombectomy per local guidelines

Exclusion Criteria

  • Posterior circulation occlusion (basilar artery excluded)
  • M2 or more distal occlusion (anterior circulation)
  • Known allergy to contrast media or heparin
  • Severe renal impairment precluding contrast use
  • Pre-existing severe disability (pre-stroke mRS ≥2)
  • Pregnancy
  • Life expectancy <6 months due to comorbidity
  • Participation in another interventional trial

Arms

FieldContact Aspiration (ADAPT)Control
InterventionFirst-line contact aspiration thrombectomy techniqueFirst-line stent retriever thrombectomy technique
DurationSingle procedureSingle procedure

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Successful revascularization (mTICI 2b/3)Primary83.1% (stent retriever)85.4% (aspiration)1.20.53
Functional independence (mRS 0-2) at 90 daysSecondary50.0%45.3%NS
Puncture-to-revascularization time (min)Secondary45380.10
Rescue therapy requiredSecondary23.8%32.8%0.05
Symptomatic ICHAdverse6.5%5.3%NS
90-day mortalityAdverse11.5%15.4%NS

Subgroup Analysis

No significant interaction by occlusion site (ICA vs M1), IV tPA pretreatment, time from onset, NIHSS severity, or age.


Criticisms

  • Primary endpoint was technical (revascularization) rather than clinical (90-day mRS)
  • Superiority design powered to detect 15% difference; not designed for noninferiority or equivalence
  • Cannot exclude smaller but clinically significant difference between groups
  • Rescue therapy at operator discretion is potential source of bias
  • All participating centers highly experienced in both techniques; may limit generalizability
  • Degree of randomness limited by stratified permuted randomization with fixed blocks of 4
  • Not powered for subgroup analyses
  • Open-label design with only endpoint blinding
  • 24-hour NIHSS assessed by unblinded treating physician

Funding

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Unrestricted research grant provided by Penumbra, Alameda, California. Funders had no role in study design, conduct, data analysis, or manuscript preparation.

Based on: ASTER (JAMA, 2017)

Authors: Bertrand Lapergue, Raphael Blanc, Benjamin Gory, ..., for the ASTER Trial Investigators

Content summarized and formatted by NeuroTrials.ai.